Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2002

View Archived Issues

HIV integrase inhibitors in early development at Merck & Co.

Delta opioid ligands reported in GSK patents

GlaxoSmithKline holds patent covering novel antibacterial mutilins

Novel MRI agents for the diagnosis of Alzheimer's disease

Substance P antagonists in the Tanabe Seiyaku pipeline

Lilly Icos presents novel phosphodiesterase inhibitors

New antidepressant disclosed in DOV patent

Intranasal and oral MOL-6131 reduces antigen-induced airways inflammation

Arrest of type 1 diabetes achieved with short-term use of antibody

Naples presentations include new clinical data for ciclesonide in asthma patients

Some clinical benefit seen in patients with MCA stenosis treated with statin

ABT-627 prevents increases in VEGF expression and neovascularization in hypercholesterolemia

Valganciclovir is safe, effective as CMV prophylaxis in kidney and pancreas-kidney transplantation

KW-7158 depresses bladder hyperactivity through afferent pathways

A possible role for the nicotinic agonist epibatidine in neurogenic voiding dysfunction

IPD-1151T may be preferable to other drugs in the treatment of interstitial cystitis

Rho kinase inhibitor attenuates hypoxia-induced pulmonary hypertension in mice

Finalization of phase III protocol for Xyotax in NSCLC and ovarian cancer

MIV-310 produces reduction in viral load in multidrug-resistant HIV patients

Neulasta recommended for approval in E.U. for reduction of chemotherapy-induced neutropenia

Pharmion acquires Refludan rights outside North America

Albany enters natural product drug discovery collaboration with Genzyme

Virulizin granted fast track designation in pancreatic cancer

Lundbeck licenses Cipralex to Mochida in Japan

Launch commences for Avinza, a modified-release formulation of morphine

MX-1094 enters phase I trial in arthritis

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...